Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond

Lung cancer is the leading cause of cancer-related mortality in both sexes, accounting for over one quarter of cancer deaths. Non-small-cell lung cancer (NSCLC) comprises 85%–90% of lung cancer diagnoses and despite advances in multimodality therapies, 5-year survival rates remain dismal with a medi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanaan, Zeyad, Kloecker, Goetz H, Paintal, Ajit, Perez, Cesar A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408973/
https://www.ncbi.nlm.nih.gov/pubmed/25945060
http://dx.doi.org/10.2147/OTT.S67262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4408973/
https://www.ncbi.nlm.nih.gov/pubmed/25945060
http://dx.doi.org/10.2147/OTT.S67262

Ejemplares similares